Light offers superb opportunities as a non-invasive regulator in biomedical applications.
A novel approach to dynamically control drug activity is within reach.
Professor Ben Feringa, Nobel Lecture 2016
LightCap Technology
Lumento's drug development platform is based on our innovative LightCap Technology. This technology was built upon the Nobel Prize winning science of professor Ben Feringa and improves existing drugs by making them light-activated, thus expanding their therapeutic potential.
Lumento Therapeutics
Lumento Therapeutics is a biotechnology company dedicated to improving the lives of cancer patients through development of light-activatable cancer drugs. Lumento has a strong management team complemented with the support of industry veterans and world-class scientists.
Pipeline
Lumento Therapeutics has several therapeutic oncology programs in its pipeline. Based on application of our LightCap Technology Platform, we are developing multiple drug candidates for various types of cancer through the lead optimization and preclinical testing phases.
Our Mission
Deliver on the promise of photopharmacology by developing new light-activatable therapeutics for cancer to improve the lives of millions of people.
Supported By
